Business Context and Reporting Period
This Form 8-K is a current report filed by Mobix Labs, Inc. (formerly Chavant Capital Acquisition Corp.) on January 22, 2024. The filing discloses material modifications to security holder rights and changes in the company's Board of Directors following the recent closing of its business combination.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. However, it details specific capital structure adjustments and transaction values:
- Warrant Exercise Price: Adjusted from $11.50 to $5.79 per share.
- Warrant Redemption Trigger Price: Adjusted from $18.00 to $9.06 per share.
- Market Value: The volume-weighted average trading price of Class A common stock over the 10-day period prior to the business combination was determined to be $4.93 per share.
- PIPE Investment: Director Michael Long purchased 300,000 shares of Class A common stock at $10.00 per share for an aggregate price of $3,000,000.
- PIPE Warrant: Mr. Long received a warrant to purchase 100,000 shares of Mobix Labs Operations common stock at an exercise price of $0.01 per share.
Material Changes Versus Prior Period
The primary material changes reported in this filing relate to the terms of outstanding warrants and the composition of the Board of Directors:
- Warrant Adjustments: Effective after the close of trading on January 4, 2024, the Company adjusted warrant terms due to the issuance of shares at an effective price of $5.03 (the "Newly Issued Price") and the Market Value being below $9.20. These adjustments were mandated by the Warrant Agreement because the gross proceeds from the issuance represented more than 60% of total equity proceeds available for the business combination.
- Board Composition: Dr. Jiong Ma resigned from the Board of Directors effective January 22, 2024. Concurrently, Mr. Michael Long was appointed as a Class III director, effective immediately, with a term expiring at the 2026 Annual Meeting.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking financial guidance, revenue outlook, or management commentary regarding future operational performance. Key contingencies and unusual items include:
- Price Protection Mechanism: Mr. Long's subscription agreement includes a price protection provision. If the 30-day volume-weighted average price (VWAP) following the effectiveness of the resale registration statement is below $10.00, Mr. Long is entitled to additional shares. The VWAP is floored at $7.00 for this calculation.
- Stockholder Approval: The exercise of the PIPE Warrant issued to Mr. Long is subject to stockholder approval, which is expected to be sought in 2024.
- Release of Claims: A Resignation and Release Agreement was executed with Dr. Ma, releasing the Company and Dr. Ma from claims against each other, subject to certain exceptions.
Important Facts for Investor Verification
- Verify the impact of the reduced warrant exercise price ($5.79) and redemption trigger ($9.06) on potential dilution and warrant holder value.
- Confirm the status of the resale registration statement required for Mr. Long's shares and the timeline for the stockholder vote on the PIPE Warrant exercise.
- Monitor the 30-day VWAP period for Mr. Long's investment to determine if the price protection mechanism triggers the issuance of additional shares.
- Review the full text of the Warrant Adjustment Notice (Exhibit 99.1) and the Subscription Agreement (Exhibit 10.1) for detailed terms and conditions.